The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development

The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another “SARS-like” threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domai...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Nan, Zhang, Yun, Zhang, Jin-Chun, Feng, Ling, Bao, Jin-Ku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier (Singapore) Pte Ltd. 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127315/
https://www.ncbi.nlm.nih.gov/pubmed/24342026
http://dx.doi.org/10.1016/j.jfma.2013.11.006
_version_ 1783516333358448640
author Zhou, Nan
Zhang, Yun
Zhang, Jin-Chun
Feng, Ling
Bao, Jin-Ku
author_facet Zhou, Nan
Zhang, Yun
Zhang, Jin-Chun
Feng, Ling
Bao, Jin-Ku
author_sort Zhou, Nan
collection PubMed
description The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another “SARS-like” threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.
format Online
Article
Text
id pubmed-7127315
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Published by Elsevier (Singapore) Pte Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71273152020-04-08 The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development Zhou, Nan Zhang, Yun Zhang, Jin-Chun Feng, Ling Bao, Jin-Ku J Formos Med Assoc Review Article The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another “SARS-like” threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs. Published by Elsevier (Singapore) Pte Ltd. 2014-03 2013-12-14 /pmc/articles/PMC7127315/ /pubmed/24342026 http://dx.doi.org/10.1016/j.jfma.2013.11.006 Text en Copyright © 2013 Published by Elsevier (Singapore) Pte Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Zhou, Nan
Zhang, Yun
Zhang, Jin-Chun
Feng, Ling
Bao, Jin-Ku
The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
title The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
title_full The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
title_fullStr The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
title_full_unstemmed The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
title_short The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
title_sort receptor binding domain of mers-cov: the dawn of vaccine and treatment development
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127315/
https://www.ncbi.nlm.nih.gov/pubmed/24342026
http://dx.doi.org/10.1016/j.jfma.2013.11.006
work_keys_str_mv AT zhounan thereceptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT zhangyun thereceptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT zhangjinchun thereceptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT fengling thereceptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT baojinku thereceptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT zhounan receptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT zhangyun receptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT zhangjinchun receptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT fengling receptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment
AT baojinku receptorbindingdomainofmerscovthedawnofvaccineandtreatmentdevelopment

Ejemplares similares